-
公开(公告)号：US20170275298A1
公开(公告)日：2017-09-28
申请号：US15505254
申请日：2015-10-26
Applicant: Merck Sharp & Dohme Corp.
Inventor： Alexander Pasternak , Shuzhi Dong , Xin Gu , Jinlong Jiang , Zhi-Cai Shi , Shawn P. Walsh , Zhicai Wu , Yang Yu , Ronald Ferguson, II , Zhiqiang Guo , Jessica Frie , Takao Suzuki , Timothy A. Blizzard , Qinghong Fu , Kelsey F. Vangelder
IPC: C07D498/10 , A61K31/435 , A61K31/501 , A61K31/506 , A61K31/444 , A61K31/5386 , A61K31/497 , A61K31/41 , A61K31/4184 , A61K31/4178 , A61K31/4422 , A61K31/55 , A61K31/401 , A61K31/675 , A61K31/551 , A61K31/4965 , A61K31/585 , C07D471/10
CPC classification number: C07D498/10 , A61K31/401 , A61K31/41 , A61K31/4178 , A61K31/4184 , A61K31/435 , A61K31/4422 , A61K31/444 , A61K31/4965 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/5386 , A61K31/55 , A61K31/551 , A61K31/585 , A61K31/675 , A61P3/14 , A61P7/10 , A61P9/12 , C07D471/10 , C07D497/10 , A61K2300/00
Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
-
公开(公告)号：US09751881B2
公开(公告)日：2017-09-05
申请号：US14908222
申请日：2014-07-28
Applicant: Merck Sharp & Dohme Corp.
Inventor： Haifeng Tang , Barbara Pio , Jinlong Jiang , Alexander Pasternak , Shuzhi Dong , Ronald Dale Ferguson, II , Zack Zhiqiang Guo , Harry Chobanian , Jessica Frie , Yan Guo , Zhicai Wu , Yang Yu , Ming Wang
IPC: C07D471/10 , C07D451/00 , C07D493/04 , C07D498/10 , A61K31/435 , A61K31/444 , A61K31/46 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5386 , A61K45/06
CPC classification number: C07D471/10 , A61K31/435 , A61K31/444 , A61K31/46 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5386 , A61K45/06 , C07D451/00 , C07D493/04 , C07D498/10
Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
-
公开(公告)号：US20160207922A1
公开(公告)日：2016-07-21
申请号：US14908222
申请日：2014-07-28
Applicant: Merck Sharp & Dohme Corp.
Inventor： Haifeng Tang , Barbara Pio , Jinlong Jiang , Alexander Pasternak , Shuzhi Dong , Ronald Dale Ferguson, II , Zack Zhiqiang Guo , Harry Chobanian , Jessica Frie , Yan Guo , Zhicai Wu , Yang Yu , Ming Wang
IPC: C07D471/10 , A61K45/06 , A61K31/435 , A61K31/506 , A61K31/5386 , C07D451/00 , A61K31/46 , A61K31/497 , C07D498/10 , A61K31/444 , A61K31/501
CPC classification number: C07D471/10 , A61K31/435 , A61K31/444 , A61K31/46 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5386 , A61K45/06 , C07D451/00 , C07D493/04 , C07D498/10
Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
Abstract translation: 本发明提供式I化合物及其药学上可接受的盐，它们是ROMK（Kir1.1）通道的抑制剂。 这些化合物可以用作利尿剂和/或利尿钠剂，并且用于治疗和预防包括心血管疾病如高血压，心力衰竭和慢性肾脏疾病以及与过量的盐和水保留有关的病症的医学病症。
-
公开(公告)号：US20150099729A1
公开(公告)日：2015-04-09
申请号：US14569858
申请日：2014-12-15
Applicant: Merck Sharp & Dohme Corp.
Inventor： Fa-Xiang Ding , Shuzhi Dong , Jessica Frie , Xin Gu , Jinlong Jiang , Alexander Pasternak , Haifeng Tang , Zhicai Wu , Yang Yu , Takao Suzuki
IPC: C07D498/20 , C07D471/20 , C07D471/10
CPC classification number: C07D498/20 , A61K31/435 , A61K31/46 , A61K31/4995 , A61K31/5386 , A61K45/06 , C07D451/00 , C07D471/10 , C07D471/20 , C07D519/00
Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.
Abstract translation: 本发明提供式I化合物及其药学上可接受的盐，它们是ROMK（Kir1.1）通道的抑制剂。 该化合物可以用作利尿剂和/或利尿钠剂，并且用于治疗和预防包括心血管疾病如高血压，心力衰竭以及与过量盐和水滞留有关的病症的医学病症。
-
公开(公告)号：US20140031349A1
公开(公告)日：2014-01-30
申请号：US13951096
申请日：2013-07-25
Applicant: Merck Sharp & Dohme Corp.
Inventor： Fa-Xiang Ding , Shuzhi Dong , Jessica Frie , Xin Gu , Jinlong Jiang , Alexander Pasternak , Haifeng Tang , Zhicai Wu , Yang Yu , Takao Suzuki
IPC: A61K31/5386 , A61K31/435 , C07D451/00 , A61K45/06 , C07D471/20 , A61K31/4995 , C07D498/20 , C07D471/10 , A61K31/46
CPC classification number: C07D498/20 , A61K31/435 , A61K31/46 , A61K31/4995 , A61K31/5386 , A61K45/06 , C07D451/00 , C07D471/10 , C07D471/20 , C07D519/00
Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.
Abstract translation: 本发明提供式I化合物及其药学上可接受的盐，它们是ROMK（Kir1.1）通道的抑制剂。 该化合物可以用作利尿剂和/或利尿钠剂，并且用于治疗和预防包括心血管疾病如高血压，心力衰竭以及与过量盐和水滞留有关的病症的医学病症。
-
Patent Agency Ranking
公开(公告)号：US08952166B2
公开(公告)日：2015-02-10
申请号：US13951096
申请日：2013-07-25
Applicant: Merck Sharp & Dohme Corp.
Inventor： Fa-Xiang Ding , Shuzhi Dong , Jessica Frie , Xin Gu , Jinlong Jiang , Alexander Pasternak , Haifeng Tang , Zhicai Wu , Yang Yu , Takao Suzuki
IPC: C07D471/10 , C07D307/88 , C07D498/20 , C07D519/00 , C07D471/20 , A61K31/438 , A61K31/46 , A61K31/435 , A61K31/4995 , A61K31/5386 , A61K45/06 , C07D451/00
CPC classification number: C07D498/20 , A61K31/435 , A61K31/46 , A61K31/4995 , A61K31/5386 , A61K45/06 , C07D451/00 , C07D471/10 , C07D471/20 , C07D519/00
Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.
Abstract translation: 本发明提供式I化合物及其药学上可接受的盐，它们是ROMK（Kir1.1）通道的抑制剂。 该化合物可以用作利尿剂和/或利尿钠剂，并且用于治疗和预防包括心血管疾病如高血压，心力衰竭以及与过量盐和水滞留有关的病症的医学病症。
-
公开(公告)号：US20220281886A1
公开(公告)日：2022-09-08
申请号：US17611553
申请日：2020-05-18
Applicant: Merck Sharp & Dohme Corp.
Inventor： Frank Bennett , Jason E. Imbriglio , Angela D. Kerekes , Tanweer Khan , Claire Lankin , Derun Li , Zhicai Wu , Yusheng Xiong , Hyewon Youm , Yang Yu , Feng Ye , Anthappan Tony Kurissery , Venukrishnan Komanduri
IPC: C07D491/107 , A61K45/06 , C07D401/14 , C07D413/14
Abstract: The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.
-
公开(公告)号：US10508108B2
公开(公告)日：2019-12-17
申请号：US15532552
申请日：2015-12-01
Applicant: Merck Sharp & Dohme Corp.
Inventor： Christian Fischer , Stephane L. Bogen , Matthew L. Childers , Francesc Xavier Fradera Llinas , J. Michael Ellis , Sara Esposite , Dawn M. Hoffman , Chunhui Huang , Solomon D. Kattar , Alexander J. Kim , John W. Lampe , Michelle R. Machacek , Daniel R. McMasters , Dann L. Parker, Jr. , Michael H. Reutershan , Nunzio Sciammetta , Pengcheng P. Shao , David L. Sloman , Wanying Sun , Feroze Ujjainwalla , Zhicai Wu , Yang Yu , Craig R. Gibeau
IPC: C07D471/04 , C07D471/14 , C07D519/00
Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R1)═ or —N═; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
-
公开(公告)号：US20170369507A1
公开(公告)日：2017-12-28
申请号：US15532549
申请日：2015-12-01
Applicant: Merck Sharp & Dohme Corp.
Inventor： Fischer Christian , Stephane L. Bogen , Matthew L. Childers , Francesc Xavier Fradera Llinas , Michael J. Ellis , Sara Esposite , Qingmei Hong , Chunhui Huang , Alexander J. Kim , John W. Lampe , Michelle R. Machacek , Daniel R. McMasters , Ryan D. Otte , Dann L. Parker, Jr. , Michael H. Reutershan , Nunzio Sciammetta , Patrick Pengcheng Shao , David L. Sloman , Feroze Ujjainwalla , Catherine White , Zhicai Wu , Yang Yu , Kake Zhao , Craig R. Gibeau
IPC: C07D498/08 , C07D471/04 , C07D498/10 , C07D471/08 , A01N43/00
CPC classification number: C07D498/08 , A01N43/00 , A61K31/551 , C07D471/04 , C07D471/08 , C07D471/14 , C07D498/04 , C07D498/10
Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
-
公开(公告)号：US20170362220A1
公开(公告)日：2017-12-21
申请号：US15532552
申请日：2015-12-01
Applicant: Merck Sharp & Dohme Corp.
Inventor： Christian Fischer , Stephane L. Bogen , Matthew L. Childers , Francesc Xavier Fradera Llinas , Michael J. Ellis , Sara Esposite , Dawn M. Hoffman , Chunhui Huang , Solomon D. Kattar , Alexander J. Kim , John W. Lampe , Michelle R. Machacek , Daniel R. McMasters , Dann L. Parker, Jr. , Michael H. Reutershan , Nunzio Sciammetta , Patrick Pengcheng Shao , David L. Sloman , Wanying Sun , Feroze Ujjainwalla , Zhicai Wu , Yang Yu , Craig R. Gibeau
IPC: C07D471/04 , C07D519/00 , C07D471/14
CPC classification number: C07D471/04 , C07D471/14 , C07D519/00
Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R1)═ or —N═; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.03 seconds)
